Episode 237 - Marc Hedrick & Russell Bradley- Cerenome

<p>In this episode of The BioHub Podcast, Ben is joined by Dr. Marc Hedrick, President &amp; CEO of Cerenome, and Russell Bradley, President &amp; General Manager of CNSide Diagnostics.</p><p>We explore why CNS cancers remain so difficult to diagnose and treat, and how Cerenome is attempting to address both sides of that problem.</p><p>Russell takes us inside CNSide®, the company’s cerebrospinal fluid-based diagnostic platform, including how it differs from traditional cytology, the importance of rare-cell characterisation, and what better diagnostic information could mean for treatment decisions.</p><p>Marc then discusses REYOBIQ™, Cerenome’s targeted radiotherapeutic platform, the challenge of delivering sufficient therapeutic intensity into the CNS while managing toxicity, and the broader opportunity to connect diagnosis, treatment and longitudinal monitoring.</p><p>A fascinating conversation at the intersection of diagnostics, therapeutics and precision CNS oncology.</p>